Cofactor Genomics is pleased to introduce our advisory board. These renowned individuals will help guide Cofactor along its trajectory of innovation while continuing to deliver positive results for our clients.
Cheryl Morley retired in 2009 as Monsanto’s Senior Vice President of Corporate Strategy. In her 26 years with the company, she held many high-level positions, including President of Animal Agricultural Group and New Business Lead in Plant Biotechnology. Prior to Monsanto, she worked with G.D. Searle, NutraSweet, and Nabisco.
Ms. Morley currently serves on multiple boards, including Ceres, Inc., Mercy Health System and the Missouri Botanical Garden Board of Trustees. She serves on the Strategic Advisory Board at Joule Unlimited and Pronutria.
A Certified Public Accountant, Ms. Morley earned a BSBA from the University of Arizona.
Dr. David Smoller is an Independent Consultant and former Chief Scientific Officer of Sigma-Aldrich. In his eight years with the company, he has also served as President of Research Biotech Business Unit and Vice President of Research and Development.
Prior to his work at Sigma-Aldrich, Dr. Smoller founded two successful St. Louis-based genomics companies, ProteoPlex and Genome Systems, Inc., leading both through their eventual acquisitions.
Dr. Smoller earned a PhD in Molecular Biology from Emory University and completed post-doctoral fellowships at Washington University and Monsanto.
Dr. Samuel Chun is Assistant Dean of Executive Programs at Olin Business School, Washington University in St. Louis, where he also holds the position of Senior Lecturer of Management Practice. He has been with the school for 12 years.
Prior to joining the Olin Business School, Dr. Chun was an Assistant Professor of Business Administration at Harvard Business School, and has served as an economist and consultant to the United States Department of Labor.
Dr. Chun earned a PhD in Business Administration from Washington University in 1995.
Dr. John Leamon is Vice President, Biology at CyVek. Dr. Leamon held multiple key scientific positions prior to CyVek, most recently as Director of Technology Integration for Ion Torrent Systems through their acquisition by Life Technologies. He served as Project Lead at RainDance Technologies and Group Leader, DNA Amplification Technology at 454 Life Sciences. A leader in the development of next-generation sequencing technology, he is a co-inventor on five published patents.
Dr. Leamon earned a PhD in Physiology and Neurobiology from the University of Connecticut and conducted postdoctoral research at Yale School of Medicine.
Rob Goltermann is Director at DCM Group, a full service real estate development and management company. Mr. Goltermann has been in commercial real estate for the past 11 years and has developed a niche with technology, pharmaceutical, and biotech related companies. He develops and owns spaces that house these types of companies as well as serves as a consultant to Wexford Science & Technologies. Having served on the board of directors of Trailnet, the Urban Land Institute, and the Saint Louis University Urban Planning and Development Board, Mr. Goltermann earned a BS in Management at Saint Louis University.
